Navigation Links
Noteworthy Medical Systems, Inc. Secures Capital from Top European eHealth Provider and Closes on Merger with Strategic Partner
Date:2/18/2009

CLEVELAND, Feb. 18 /PRNewswire/ -- Noteworthy Medical Systems, Inc., a leading provider of connected healthcare technology solutions for the ambulatory sector, and CompuGROUP Holding AG, the leading European eHealth service provider with headquarters in Koblenz, Germany, announced today that CompuGROUP has completed a substantial equity investment in privately-held Noteworthy.

"CompuGROUP's investment will allow Noteworthy to continue to grow its market share and build on its unique ability to provide connectivity to health systems throughout the U.S. It is a natural and very significant, exciting next step in our strategic plan and vision of our future in healthcare technology," said Lawrence Dolin, Noteworthy's chairman of the board and chief executive officer.

The announcement comes in conjunction with Noteworthy's merger with strategic partner ChartConnect, Inc., based in Yakima, Wash., a provider of turn-key health information exchange (HIE) and web-based electronic health record (EHR) applications. Noteworthy has experienced unprecedented sales growth amidst the integration of both ChartConnect and MARS Medical Systems, Inc., based in Phoenix, Arizona, a leader in practice management solutions. Such strategic moves have completed Noteworthy's software suite, which includes web-based practice management and EHR applications, hastening the company's market share expansion and presence within the ambulatory space.

Noteworthy has added nearly 500 new providers and 1800 NetPracticeEHR/PM users to a customer base that extends across 43 states. Sales in 2008 were 68% over 2007, with record-breaking sales quarters in 2008.

"We've enjoyed steady growth in both sales and revenue this past year and we're anticipating an even more robust 2009," said Paul Ruflin, Noteworthy's president and chief operating officer. "Given the Obama administration's priority on funding healthcare IT initiatives
'/>"/>

SOURCE Noteworthy Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Taxol with avastin produces noteworthy results
2. Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy
3. American Veterinary Medical Association: Weaving a Web for Food Safety
4. Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform
5. Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimers Disease
6. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
7. HUYA Bioscience International Announces Collaboration Agreement With the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
8. Greenway Medical Technologies Assists Capitol Hill With Shaping of The Presidents Stimulus Package
9. Emergency medical professionals support their participation in prevention programs
10. Medical prescription of heroin does not pose neighborhood risk
11. Mutant rats offer clues to medical mystery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2American Chemical Societys Weekly PressPac June 3 2009 8740 1American Chemical Societys Weekly PressPac June 3 2009 8740 2American Chemical Societys Weekly PressPac June 3 2009 8740 3American Chemical Societys Weekly PressPac June 3 2009 8740 4American Chemical Societys Weekly PressPac June 3 2009 8740 5American Chemical Societys Weekly PressPac June 3 2009 8740 6American Chemical Societys Weekly PressPac June 3 2009 8740 7American Chemical Societys Weekly PressPac June 3 2009 8740 8American Chemical Societys Weekly PressPac June 3 2009 8740 9American Chemical Societys Weekly PressPac June 3 2009 8740 10Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference 48171 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 1Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 2Video 3A CVS pharmacy Kicks Off 8th Annual ALS Fundraising Campaign in Stores Nationwide 48169 3